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Summary The expression of tumour markers CA 19-9 and CA 50, defined by the monoclonal antibodies 1116
NS 19-9 (19-9 antibody) and C 50, was studied by the immunoperoxidase technique in formalin-fixed, paraffin-
embedded tissue sections from 11 hepatocellular carcinomas and 10 cholangiocarcinomas of the liver, and
from specimens of normal liver and liver cirrhosis. The 19-9 and C 50 antibodies react with sialosylfuco-
syllactotetraose, corresponding to sialylated blood group antigen Lewisa, and the C 50 antibody also with
another sugar moiety, sialosyllactotetraose. Neither marker was cancer specific. The CA 19-9 and CA 50
antigens are normal constituents of bile ducts. Nine out of 10 cholangiocarcinomas stained for CA 50, and
eight out of 10 for CA 19-9. There was no apparent difference between the staining pattern of CA 19-9 and
CA 50. Hepatocellular carcinomas were consistently negative for both markers. Thus, hepatocellular carcin-
omas and cholangiocarcinomas showed a clear difference in the reactivity for tumour marker antigens CA 19-9
and CA 50. This difference might be of clinical importance in the differential diagnosis between hepatocellular
carcinoma and cholangiocarcinoma.
Immunohistochemically, the CA 19-9 antigen (Koprowski et
al., 1979) has been demonstrated in various gastrointestinal
carcinomas, such as pancreatic and biliary tract cancer, and
also in many normal tissues, among others in pancreatic
ducts, gallbladder, extra- and intrahepatic bile ducts, but not
in hepatocytes (Atkinson et al., 1982; Arends et al., 1983;
Haglund et al., 1986a). The CA 50 antigen (Lindholm et al.,
1983) has been detected in tissue extracts from various
gastrointestinal and non-gastrointestinal epithelial tumours:
pancreatic, colorectal, gastric, gall bladder, lung, urinary
bladder, and liver cell carcinomas, as well as carcinomas of
the breast and uterine cervix (Nilsson et al., 1983). Benign
and malignant pancreatic lesions express CA 50 (Haglund et
al., 1986b), but CA 50 has not been reported in hepatobiliary
lesions.
In this work, we have studied the tissue expression of
CA 19-9 and CA 50 in hepatocellular carcinomas and intra-
hepatic cholangiocarcinomas, as well as in normal liver tissue
and liver cirrhosis.
Materials and methods
Specimens
The following specimens were studied: 11 hepatocellular car-
cinomas; ten cholangiocarcinomas of the liver; four samples
of liver cirrhosis; and five samples of normal liver tissue. In
addition, histologically normal liver tissue was seen in 16
specimens obtained from livers with carcinoma (all chol-
angiocarcinomas and half of the hepatocellular carcinomas).
The samples were formalin-fixed, paraffin-embedded surgical
specimens, which had been stored for between 1 and 11
years.
Antibodies
Tissue culture supernatants containing mouse monoclonal
antibodies 1116 NS 19-9 (IgGi) and C 50 (IgM) were used
for the CA 19-9 and CA 50 stainings. The antibodies were
obtained from H. Koprowski (Philadelphia, USA) and L.
Lindholm (Gothenburg, Sweden).
Stainingprocedure
Paraffin sections 5 gsm thick were deparaffinised and treated
with 0.4% pepsin (2500 FIP-U/g, Merck, Darmstadt, Ger-
many) in 0.01 N HCI for 1 h at 37°C. All sections were then
incubated in 0.5% hydrogen peroxide in methanol for 30 min
to block endogenous peroxidase, incubated with non-immune
horse serum, diluted 1:20, and then reacted with the primary
antibody supernatant; the C 50 antibody was diluted 1:20
and the 1116 NS 19-9 antibody 1:50. Bound antibody was
visualized by the avidin-biotin complex assay (ABC) (Vectas-
tain, Vector, Burlingame, CA): the sections were successively
treated with biotinylated antimouse immunoglobulin
antiserum, avidin, and biotinylated horse-radish peroxidase
complex. Each step was followed by washing in phosphate-
buffered saline (PBS). Finally, sections were incubated with
3-amino-9-ethyl-carbazole (AEC) and hydrogen peroxide,
and then counterstained with hematoxylin. Sections stained
with normal mouse serum and PBS served as negative con-
trols.
Controls
The following controls were used: (1) A known CA 19-9 and
CA 50 positive specimen of pancreatic carcinoma served as
positive control in each series. (2) Sialic acid in the sialosyl-
fucosyl-lactotetraose residue was removed with neuraminidase.
Sections were incubated with 0.3 U ml-' Vibrio cholerae
neuraminidase (1 U ml-') (Behringwerke, Marburg, Ger-
many), diluted with PBS containing 0.9 mM Ca2" and
0.5 mM Mg2+ for 2 h at 37°C to remove sialic acid before
incubation with the primary antibodies. Sections incubated
with buffer only served as negative controls.
Results
Normal liver
In all five specimens, many large and middle size bile ducts
stained for CA 19-9 and CA 50 (Figure la and b). In addi-
tion, small foci of positive cells were seen inside the liver
parenchyma. These cells do not look like hepatocytes and
probably represent interlobular bile ducts. In most specimens
the CA 50 staining was more intense.
In histologically normal liver tissue adjacent to carcinoma,
small biliary ducts and part of the large bile ducts stained
positively for CA 50 in all specimens. CA 19-9 was expressed
in some small bile ducts in one specimen. In all other speci-
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Figure 1 Normal liver tissue. Immunoperoxidase staining with Figure 2 Liver cirrhosis. Immunoperoxidase staining with the
the 1116 NS 19-9 a, and C 50 b antibodies, counterstained with 1116 NS 19-9 a, and C 50 b antibodies, counterstained with
hematoxylin. Small interlobular bile ducts are positive for CA 19- hematoxylin. Bile ducts stain for CA 19-9 and CA 50. Bar = 100
9 and CA 50 and in addition one bile duct in the portal area for tLm.
CA 50. Bar=100jLm.
mens a positive CA 19-9 staining was observed in part of the W.
large bile ducts only, but not in the small interlobular bile
ducts. ..
Liver cirrhosis
In areas of proliferation of bile ducts, the ductal epithelium ~ -..
stained strongly for both CA 50 and CA 19-9 (Figure 2a andin
b). No clear difference was seen between the markers. The
interlobular bile ducts expressed CA 19-9 and CA-5O like in
normal liver.
Hepatocellular carcinomas H
Large bile ducts between foci of hepatocellular carcinoma
stained positively both for CA 50 and CA 19-9. The staining
for CA 50 was usually more uniform. Benign looking struc-
tures within the carcinoma stained positively for CA 50 in I
five out of 11I specimens and for CA 19-9 in one specimen..
These structures are similar to those structures which stained W..,. :
positively in normal liver. Tumour cells of hepatocellular
carcinomas were consistently negative for both markers ...
.....
(Figure 3a and b).
Cholangiocarcinomas 4 4
Nine out of 10 cholangiocarcinomas stained positively for ,
CA 50, and eight out of 10 for CA 19-9. The positivity was
predominantly seen in the apical part of the carcinoma cells, -i .
but in many cells a diffuse intracytoplasmic staining was seen .
(Figure 4a and b). There was no apparent difference between
the expression of CA 19-9 and CA 50. Figure 3 Hepatocellular carcinoma. immunoperoxidase staining
with the 1116 NS 19 9 a, and C 50 b antibodies, counterstained
Neuraminidase treatment with hematoxylin. A large bile duct stain for CA 19 9 and CA 50,
whereas small bile ducts within the carcinoma (arrow) stain
Incubation of specimen with 0.3 U ml-' neuraminidase abol- positively only for CA 50. Hepatocellular carcinoma cells are
ished the CA 19-9 and CA 50 staining reactions. negative. Bar 1 I00 lim
387388 C. HAGLUND et al.
.: : { . ...
Figure 4 Cholangiocarcinoma of the liver. Immunoperoxidase
staining with the 1116 NS 19-9 a, and C 50 b antibodies,
counterstained with hematoxylin. Tumour cells stain for CA 19-9
and CA 50. Bar= 100gm.
Discussion
Monoclonal antibodies 1116 NS 19-9 (19-9-antibody) and
C 50 have been obtained after immunisation of mice with
human colonic adenocarcinoma cell lines SW 1116 and
COLO 205, respectively (Koprowski et al., 1979; Lindholm et
al., 1983). Both antibodies react with sialosyl-fucosyl-lacto-
tetraose, corresponding to sialylated blood group antigen
Lewis' (Magnani et al., 1982; Mansson et al., 1985). In
addition, the C 50 antibody reacts with a least one other
carbohydrate structure, the sialosyl-lactotetraose, which lacks
the fucose moiety of sialylated Lewis' (Nilsson et al., 1985).
Thus, the C 50 antibody does not require the fucosyl moiety
of the sugar chain of the Lea structure for binding.
Immunoperoxidase staining has previously been shown to
be a reliable method of demonstrating the CA 19-9 and
CA 50 antigens in formalin-fixed, paraffin-embedded speci-
mens. The optimal staining result is obtained after enzyme
pretreatment (Haglund et al., 1986a,b)
Our results show that the CA 19-9 and CA 50 antigens are
normal constituents of bile ducts. There was a slightly
stronger expression of CA 50, which might reflect the
broader reactivity of the C 50 antibody.
Hepatocellular carcinomas and cholangiocarcinomas show-
ed a clear difference in the expression of tumour marker
antigens CA 19-9 and CA 50. Tumour cells of hepatocellular
carcinomas did not express these antigens at all. On the other
hand, most cholangiocarcinomas (80-90%) stained for both
CA 19-9 and CA 50. The staining pattern was similar to that
of pancreatic carcinomas (Haglund et al., 1986a,b). Thus it
seems, that the difference between hepatocellular carcinoma
and cholangiocarcinoma is more pronounced using staining
for CA 19-9 or CA 50 than it is with carcinoembryonic
antigen (CEA) or alpha-foetoprotein (AFP). CEA can be
found in both cholangiocarcinomas and hepatocellular car-
cinomas (Kojiro et al., 1981; Goodman et al., 1985). Alpha-
foetoprotein is expressed in 35-73% of hepatocellular
carcinomas, but not in cholangiocarcinomas (Thung et al.,
1979; Kojiro et al., 1981; Goodman et al., 1985).
Most cholangiocarcinomas show immunohistochemical
reactivity for CA 19-9 and CA 50. This is in concordance
with the expression of these antigens in serum. Elevated
serum levels of CA 19-9 (67-73%) and CA 50 (58%) are
frequently seen in patients with bile duct carcinomas (Jal-
anko et al., 1984; Ritts et al., 1984; Kuusela et al., 1987).
Hepatocellular carcinomas do not stain for either marker.
Yet, some patients with hepatocellular carcinoma have
elevated CA 19-9 (22%) and CA 50 levels (54-78%) in
serum (Jalanko et al., 1984; Chan et al., 1985; Habib et al.,
1986; Kuusela et al., 1987). An explanation for elevated
CA 50 and CA 19-9 levels in serum of patients with hepato-
cellular carcinomas might be that CA 50 and CA 19-9 is
produced by the tumour, but that the serum levels are more
sensitive than immunohistochemical staining. However,
previous works on pancreatic cancer speak against that
theory, as some patients with pancreatic cancer had a strong
tissue expression of CA 19-9 and CA 50, but normal serum
levels (Haglund et al., 1986a,b). Furthermore, the percentage
of positive serum samples in patients with hepatocellular
carcinomas is not greater than the percentage of positive
samples in patients with benign liver diseases (Jalanko et al.,
1984; Chan et al., 1985; Haglund et al., 1987; Kuusela et al.,
1987). Therefore, we do not think that hepatocellular carcin-
omas produce neither CA 19-9 nor CA 50.
The reason for the higher frequency of elevated CA 50
than CA 19-9 serum values in liver cirrhosis is not known.
Immunohistochemically, both CA 50 and CA 19-9 were
strongly and widely expressed, and no difference between
these markers could be demonstrated. The C 50 antibody
reacts, in addition to sialylated Lewisa with at least one other
antigenic determinant, sialosyllactotetraose (Nilsson et al.,
1985). This carbohydrate structure could be shed into the
blood stream and explain the difference between the expres-
sion of the markers.
The reactivity for CA 19-9 and CA 50 in cholangiocarcin-
omas may be of importance in the differential diagnosis with
hepatocellular carcinoma. On the other hand, cholangiocar-
cinomas of the liver cannot be distinguished from metastatic
liver disease. Other gastrointestinal tumours, such as pan-
creatic, extrahepatic bile duct, gastric and colorectal car-
cinomas often express CA 19-9 and CA 50 (Atkinson et al.,
1982; Arends et al., 1983; Nilsson et al., 1983; Haglund et al.,
1986a,b), and primary tumours of these organs must be
excluded by other diagnostic methods.
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